JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Top Cited Papers
Open Access
- 6 March 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (10), 1544-1551
- https://doi.org/10.1182/blood-2013-11-539098
Abstract
Key Points JAK2 (V617F)-mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm. CALR-mutated essential thrombocythemia is a distinct disease entity not only at the molecular level, but also with respect to clinical outcomes.This publication has 36 references indexed in Scilit:
- Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasmsBlood, 2013
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)Blood, 2012
- JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneBlood, 2012
- JAK/STAT signaling in hematological malignanciesOncogene, 2012
- Calreticulin signaling in health and diseaseThe International Journal of Biochemistry & Cell Biology, 2012
- Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasmsHaematologica, 2011
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 SignalingCancer Cell, 2010
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999